Additional file 1 of Knowledge and perception of biosimilars in ambulatory care: a survey among Belgian community pharmacists and physicians
Additional file 1: Figure S1. Familiarity with and knowledge about biosimilars among community pharmacists and physicians. Figure S2. Additional question on the self-assessed competence of community pharmacists to dispense biologicals (in general) and biosimilars (in particular). Figure S3. Opinion of community pharmacists about the organisation of a counselling treatment conversation for patient biosimilar use. Figure S4. Additional questions posed to community pharmacists and physicians regarding interchangeability. Figure S5. Additional questions posed to community pharmacists and physician... Mehr ...
| Verfasser: | |
|---|---|
| Dokumenttyp: | Text |
| Erscheinungsdatum: | 2021 |
| Schlagwörter: | Medicine / Sociology / Science Policy / Biosimilar / Biologic / Community pharmacist / Physician / Healthcare professional / Primary care / Ambulatory care / Interchangeability / Pharmacy substitution |
| Sprache: | unknown |
| Permalink: | https://search.fid-benelux.de/Record/base-26913966 |
| Datenquelle: | BASE; Originalkatalog |
| Powered By: | BASE |
| Link(s) : | https://doi.org/10.6084/m9.figshare.14825927.v1 |
Additional file 1: Figure S1. Familiarity with and knowledge about biosimilars among community pharmacists and physicians. Figure S2. Additional question on the self-assessed competence of community pharmacists to dispense biologicals (in general) and biosimilars (in particular). Figure S3. Opinion of community pharmacists about the organisation of a counselling treatment conversation for patient biosimilar use. Figure S4. Additional questions posed to community pharmacists and physicians regarding interchangeability. Figure S5. Additional questions posed to community pharmacists and physicians regarding substitution. Figure S6. Additional questions posed to community pharmacists and physicians regarding information and training needs. Figure S7. Reasons why physicians would not prescribe a biosimilar. Figure S8. Questions about the need for incentives to stimulate biosimilar prescription in the ambulatory setting.